Pfizer (NYSE: PFE) reported flat third-quarter revenue of $16.6 billion and raised its full-year outlook. Shares slipped about 0.2% in premarket trading. Eliquis and other newer drugs offset the drop in COVID and Prevnar sales, but the growth leaned on price, and adjusted earnings held only because offsetting items balanced out. Revenue: $16.6 billion, relatively flat versus a year ago. Revenue excluding Comirnaty and Paxlovid: up 7% operationally.
CryptoAlerta — análise de criptomoedas e mercado em tempo real